Fibromyalgia was not discovered in a single moment but rather emerged gradually over centuries, with each era layering new medical language and understanding onto a condition that patients had been experiencing all along. Descriptions of widespread muscle pain date back hundreds of years under the umbrella of “rheumatism,” but the modern concept of fibromyalgia took shape in the 1970s and received its first formal classification criteria in 1990. The path from vague clinical curiosity to recognized diagnosis has been slower and more contentious than for most other chronic conditions, and the story is still unfolding.
Centuries of Muscle Pain Without a Name
Long before anyone used the word “fibromyalgia,” physicians wrote about patients suffering from diffuse, hard-to-explain musculoskeletal pain. For centuries this was simply called rheumatism, later refined to “muscular rheumatism” as doctors tried to distinguish it from joint-centered diseases like rheumatoid arthritis.1Current Pain and Headache Reports. History of fibromyalgia: past to present The problem was that nobody could find anything structurally wrong with the muscles. There was no inflammation visible under a microscope, no joint erosion, nothing to point to. That gap between the patient’s suffering and the doctor’s inability to find a cause would define fibromyalgia’s troubled relationship with mainstream medicine for the next several generations.
In 1904, the British neurologist Sir William Gowers introduced the term “fibrositis” to describe what he believed was inflammation of fibrous tissue. The name stuck for decades, even though researchers were never able to confirm that any actual inflammation existed in the tissues of people with the condition.1Current Pain and Headache Reports. History of fibromyalgia: past to present The “-itis” suffix (meaning inflammation) was a misnomer from the start, and it helped set up a long period of confusion. If the tissue was not inflamed, what exactly was going on?
The 1970s Breakthrough
The modern understanding of fibromyalgia traces to two key developments in the early-to-mid 1970s. In 1972, the Canadian researcher Hugh Smythe laid the groundwork by describing a pattern of widespread pain paired with specific “tender points,” areas on the body that were unusually sensitive to pressure.1Current Pain and Headache Reports. History of fibromyalgia: past to present This was the first real attempt to define the condition as a distinct clinical entity rather than a vague complaint.
A few years later, Harvey Moldofsky and his colleagues published a sleep study that added a biological dimension. They found that patients with “fibrositis syndrome” showed an unusual pattern in their sleep: alpha brain rhythms intruded into the deep stages of non-REM sleep, a phenomenon they called alpha-delta sleep. The same disrupted pattern appeared in healthy volunteers who were experimentally deprived of deep sleep, and those volunteers went on to develop musculoskeletal symptoms resembling fibrositis.2PubMed. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects For the first time, there was measurable laboratory evidence that something was physically different in these patients.
In 1976, the name was officially changed from “fibrositis” to “fibromyalgia,” combining the Latin “fibra” (fiber), the Greek “myo” (muscle), and “algos” (pain). The new name dropped any implication of inflammation, which was a quiet but important concession that the old framework had been wrong.1Current Pain and Headache Reports. History of fibromyalgia: past to present
The 1990 Classification Criteria
The single most important event in fibromyalgia’s journey toward medical legitimacy was the publication of the American College of Rheumatology’s 1990 classification criteria. A multicenter study established that the combination of widespread pain lasting at least three months and tenderness at 11 or more of 18 specified body sites could identify fibromyalgia patients with roughly 88% sensitivity and 81% specificity.3PubMed. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia For the first time, doctors had a standardized way to diagnose the condition, and researchers had a common language to use in studies.
The impact was enormous. Research output surged, and investigators began building a more detailed picture of how the condition worked.4Nature Reviews Rheumatology. Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria But the criteria also had flaws that became apparent over the next two decades. The tender point exam was subjective, hard to standardize across clinicians, and many doctors outside of rheumatology never learned to perform it correctly. Some patients with clear fibromyalgia symptoms fell just short of the 11-point threshold and were left without a diagnosis.
Evolving Diagnostic Criteria After 2010
By 2010, enough problems with the tender point approach had accumulated that the ACR published a new set of preliminary diagnostic criteria. These replaced the physical tender point exam with two questionnaire-based scales: one measuring where pain occurred across the body and another capturing cognitive problems, unrefreshed sleep, fatigue, and other somatic symptoms.5PubMed. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity The shift recognized that fibromyalgia is not just a pain condition but a syndrome involving sleep disruption, mental fog (often called “fibro fog”), and fatigue.
A further revision came in 2016, addressing a problem with the 2010 criteria: they could misclassify people who had pain concentrated in one region rather than spread throughout the body. The fix was a “generalized pain criterion” requiring that the pain be present in at least four of five body regions, which eliminated the misclassification issue.6PubMed. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria The 2016 criteria are the most current version used in clinical practice, though some clinicians still refer to the older frameworks.
The Long Shadow of Psychological Dismissal
One reason fibromyalgia’s path to recognition took so long is that for decades it was tangled up with assumptions about mental health. During the 1950s and onward, the condition developed from a murky category of “difficult to explain” widespread pain mixed heavily with symptoms that doctors attributed to psychosocial distress.7PubMed Central. The Evolution of Fibromyalgia, Its Concepts, and Criteria The implication, often stated bluntly, was that the pain was not real, or that it was a physical expression of depression and anxiety rather than its own condition.
That framing did real damage. Patients, the majority of whom were women, were routinely told their symptoms were “all in their head.” Many went years or decades without a diagnosis. Skeptics within rheumatology itself argued that fibromyalgia was not a legitimate disease but merely a label for unhappy patients. While psychological factors like depression and anxiety do co-occur with fibromyalgia at higher-than-average rates, the evidence accumulated since the 1990s has decisively shown that the condition has distinct biological underpinnings. The controversy has not fully disappeared, but the terms of the debate have shifted dramatically.
Central Sensitization and What Brain Scans Show
The leading explanatory framework that emerged in the 2000s is central sensitization: the idea that fibromyalgia involves an amplification of pain signals within the central nervous system. The brain and spinal cord essentially turn up the volume on incoming sensory information, so that stimuli that would barely register in a healthy person become painful. Fibromyalgia has been grouped with other conditions sharing this feature, including irritable bowel syndrome, chronic fatigue syndrome, and tension headaches, under the umbrella of “central sensitivity syndromes.”8PubMed. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes
Brain imaging has provided some of the most persuasive evidence for this model. In one study using functional MRI, fibromyalgia patients showed a full pain-network response to mild pressure that caused little reaction in healthy volunteers. When the pressure applied to healthy subjects was increased until they reported the same pain level, both groups activated similar brain areas, but fibromyalgia patients still showed significantly larger activation in the anterior insula and cingulate cortex, regions involved in the emotional processing of pain.9PLOS ONE. Mapping Brain Response to Pain in Fibromyalgia Patients Using Temporal Analysis of fMRI A systematic review of neuroimaging studies concluded that task-based brain scans provided the clearest support for central sensitization, showing exaggerated responses in pain-processing networks along with weakened activity in brain pathways that normally dampen pain signals.10PubMed Central. Structural and Functional Neuroimaging Findings in Fibromyalgia: A Systematic Review
Some imaging studies have found subtler or more complex results. One case-control study using a different scanning technique found reduced blood flow in certain prefrontal and temporal brain areas in fibromyalgia patients, but those reductions did not correlate with the patients’ actual pain intensity or disability.11PLOS ONE. Altered central pain processing in fibromyalgia—A multimodal neuroimaging case-control study using arterial spin labelling The brain changes are real, but mapping them neatly onto symptoms remains a work in progress.
FDA Drug Approvals as a Turning Point
Another milestone in fibromyalgia’s recognition came from an unexpected direction: the pharmaceutical industry. When the U.S. Food and Drug Administration approved pregabalin (Lyrica) for fibromyalgia treatment in 2007, it sent a powerful institutional signal that fibromyalgia was a real, treatable medical condition.12PubMed Central. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia Approvals of duloxetine and milnacipran followed. None of these drugs are cures, and many patients find the relief they provide modest at best, but their regulatory approval meant that fibromyalgia had cleared a threshold: it was now a condition for which treatments could be tested in clinical trials, sold by pharmaceutical companies, and covered by insurance.
Small Fiber Neuropathy and the Peripheral Piece
Central sensitization puts the problem in the brain and spinal cord, but research in the 2010s revealed that some fibromyalgia patients also have measurable damage to tiny nerve fibers in the skin. One study found that about 41% of fibromyalgia patients had diagnostic evidence of small fiber polyneuropathy on skin biopsy, compared to 3% of healthy controls.13PAIN®. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia A later meta-analysis put the figure closer to half of all fibromyalgia patients.14PubMed Central. Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review
This matters for two reasons. First, small fiber neuropathy is an objective, testable finding, something you can see under a microscope. For a condition long dismissed as subjective, that carries weight. Second, small fiber neuropathy has known causes in some cases (diabetes, autoimmune conditions) and can sometimes be treated. The implication is that a meaningful fraction of people carrying a fibromyalgia diagnosis may have a more specific, potentially treatable nerve condition hiding underneath the broader label.
Genetics and Family Patterns
Fibromyalgia runs in families, and genetic research has confirmed that this is not just shared environment. Genome-wide studies suggest that genetic factors may account for roughly half of a person’s susceptibility to the condition.15PubMed Central. Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers Several candidate genes have been identified, including genes involved in ion channels and neuronal development, though none is anything close to a single “fibromyalgia gene.”16PubMed Central. New insights into the genetics of fibromyalgia The picture looks more like many small genetic contributions interacting with environmental triggers such as physical trauma, infection, or prolonged stress. This polygenic pattern resembles other complex conditions and helps explain why fibromyalgia is common (affecting roughly 2-4% of the population) yet does not follow any simple inheritance pattern.
The Autoimmune Hypothesis
Perhaps the most striking recent development in fibromyalgia science came from a 2021 study that tested whether antibodies from fibromyalgia patients could transfer symptoms to mice. The answer was yes. Mice injected with purified IgG antibodies from fibromyalgia patients developed increased sensitivity to pressure and cold, reduced grip strength, and decreased physical activity. Mice that received antibodies from healthy donors, or antibody-depleted serum from patients, showed none of those effects.17PubMed Central. Passive transfer of fibromyalgia symptoms from patients to mice The patient antibodies appeared to act on nerve cells in the dorsal root ganglia, relay stations where sensory signals enter the spinal cord.
If this autoimmune mechanism holds up, it would represent a fundamental shift in understanding. Fibromyalgia would move from “we don’t fully understand what causes this” to “the immune system is attacking sensory nerves,” opening the door to therapies that reduce antibody levels, similar to treatments for other autoimmune diseases.18Nature Reviews Rheumatology. Antibodies induce fibromyalgia symptoms Replication studies are underway, and the findings remain preliminary. But the work has generated genuine excitement in a field that has spent decades struggling to pin down a clear biological mechanism.
Children and Adolescents Get It Too
Fibromyalgia is not exclusively an adult condition. Juvenile primary fibromyalgia syndrome affects children and adolescents, most commonly adolescent girls.19PubMed Central. Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis The condition in young people looks broadly similar to the adult version, with widespread pain, fatigue, and sleep problems, but diagnosis can be even more challenging. Pediatricians may not think of fibromyalgia, parents may assume growing pains, and the overlap with school-related stress and mood disorders complicates the picture. Awareness that fibromyalgia can begin in childhood has grown, but it remains underdiagnosed in younger populations.
Gut Bacteria as a New Frontier
One of the more unexpected research directions involves the gut microbiome. A 2019 study found that fibromyalgia patients had a distinctly different composition of gut bacteria compared to healthy controls, with reduced diversity and lower levels of certain bacterial groups involved in neurotransmitter metabolism, including Bifidobacterium and Eubacterium. Their blood also showed altered levels of glutamate and serine, both tied to how the nervous system processes signals.20PubMed Central. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia
Another study that same year found differences in gut bacteria that correlated with clinical fibromyalgia measures, along with altered blood levels of short-chain fatty acids like butyrate. Notably, a machine-learning algorithm trained on the microbiome data alone could distinguish fibromyalgia patients from controls with roughly 88% accuracy.21PubMed. Altered microbiome composition in individuals with fibromyalgia A review of this evidence has suggested that gut bacteria or their metabolites could eventually serve as biological markers for the condition, something fibromyalgia currently lacks.22PubMed Central. Decoding the connection: unraveling the role of gut microbiome in fibromyalgia
Whether the microbiome differences are a cause, a consequence, or a bystander of fibromyalgia is unknown. But the gut-brain axis, the communication network linking intestinal bacteria to the central nervous system, offers a plausible route by which changes in gut flora could influence pain sensitivity and fatigue. If validated, microbiome-based diagnostics or treatments like targeted probiotics could eventually complement existing approaches. For now, the findings are promising but early-stage, and no microbiome-based test or therapy is clinically available for fibromyalgia.